



DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty members have indicated that they do not have any relevant financial relationships with ineligible companies* to disclose. **Indicates that this individual's presentation(s) ***will include*** discussion of off-label or unapproved usage.

Larry Bush, M.D.

The following faculty members have indicated that they do have relevant financial relationships with ineligible companies* to disclose.

Eric F. Martin, M.D., faculty of this educational activity, is on the speakers' bureau for Gilead, Dr. Martin is also a consultant for Gilead and Dova; He is also an advisor for Dova pharmaceuticals and has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Eamonn M. M. Quigley, M.D., faculty of this educational activity, is a researcher for 4D Pharma, Biomerica, and Vibrant. Dr. Quigley is also a consultant for 4D Pharma, Vibrant, Precisionbiotics, Novozymes, Salix, and Allergan; He is also an advisor for Atlantia Foods and has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Faten N. Aberra, M.D., faculty of this educational activity, is a researcher for Abbvie, Pfizer, Janssen, Target PharmaSolutions, and UCB has indicated that the presentation or discussion will include off-label or unapproved product usage.

All of the relevant financial relationships listed for these individuals have been mitigated.

Other individuals involved in planning, content review, approval, or moderating for this educational activity have no relevant financial relationships to disclose with ineligible companies*.

**Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*